Following FDA Approvals, CML Pipeline Has Challenges

April 24, 2018 – The past year has seen the release of data regarding advances in the treatment of patients with chronic myeloid leukemia (CML), including some leading to recent regulatory approvals, but remaining challenges include conceptualizing treatment-free remission and optimal sequence of therapies. In December 2017, the FDA approved bosutinib for patients with Philadelphia chromosome-positive (Ph+) CML, based on findings from the BFORE … (leggi tutto)